Savara: A High-Risk Opportunity

Core Insights - Savara, Inc. (SVRA) shares have rebounded over 100% following a refuse-to-file letter from the FDA regarding its clinical candidate molgramostim in May 2025 [2] Company Overview - Savara, Inc. is focused on respiratory diseases and has seen significant stock price recovery after regulatory challenges [2] Market Analysis - The rebound in Savara's stock is attributed to the company's strategic alignment and market sentiment, indicating potential investor interest in biotech stocks [2]